arrow
S

Simon Waters

Velindre Cancer Centre
H指数:21
被引数:2,849

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

一项III期临床试验,比较在激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌患者中,辅助瑞博西尼联合内分泌疗法与单独内分泌疗法的效果:NATALEE试验的最终浸润性疾病无进展生存结果

2025-02-017
PRE
Efficacy and safety of ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2-early breast cancer (EBC) in NATALEE

瑞博西利(RIB)联合非甾体类芳香化酶抑制剂(NSAI)在年轻激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌(EBC)患者(pts)中的疗效与安全性研究(NATALEE研究)。

2024-09-011
PRE
Tracking triple negative breast cancer (TNBC) evolution in the molecular residual disease (MRD) setting in the c-TRAK TN clinical trial
2024-03-220
PRE
Invasive diseaseefree survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HRD/HER2-early breast cancer (EBC)
2023-10-013
PRE
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
2023-03-027
OAAI
MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01)
2023-03-012
PRE
Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial
2023-03-011
PRE
EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
2023-03-0120
PRE
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
2023-02-0164
OAAI
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer
BREAST
IF7.9
2022-12-014
OAAI
Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression
BREAST
IF7.9
2022-08-0114
OAAI
Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer
2022-02-1510
PRE
Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
2022-02-157
PRE
MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
2021-09-011
OAAI
Biomarker Analysis of the Phase III NALA Study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
2021-08-1116
OAAI
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

帕妥珠单抗联合曲妥珠单抗和紫杉烷一线治疗HER2-positive局部复发或转移性乳腺癌的初步安全性和有效性 (PERUSE)

2019-05-0189
OAAI